(Reuters) - Biotechnology stocks will be in the spotlight with a trans-Atlantic takeover deal in the works and Amgen Inc. set to report quarterly earnings after the closing bell.
Anglo-Swedish drug maker AstraZeneca has agreed to buy U.S. biotech company MedImmune Inc. for more than $15 billion. MedImmune stock shot up 18.5 percent to $56.90 in electronic trading before the bell.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment